Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer : A Multicenter Real-World Study
Objectives: The ABC-06 and the NIFTY trials recently established the role of second-line chemotherapy (2L) in patients with advanced biliary tract cancer (BTC). Our real-world study aimed to explore 2L in BTC patients aged ≥ 70 years old and to compare their outcomes with younger subjects. Methods: Institutional registries across three academic medical centers were retrospectively reviewed. The Kaplan−Meier methods were used to estimate survival, and the log-rank test was used to make comparisons. Results: A total of 190 BTC patients treated with 2L were identified and included in the analysis. Among them, 52 (27.3%) were aged ≥ 70 years (range 70−87 years). No statistically significant differences in both median overall survival (mOS) and median progression-free survival (mPFS) were recorded between the elderly and younger patients. Absolute lymphocyte count < 1000/mmc (p < 0.001) and albumin level < 3 g/dL (p < 0.001) were independently associated with worse prognoses. Conclusions: The results of this real-world study suggest that for patients aged ≥ 70 years, 2L could be equally effective for younger patients with survival outcomes aligned to those from the ABC-06 and NIFTY trials. The delivery of 2L should be carefully evaluated and monitored in this patient subset.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Medicina (Kaunas, Lithuania) - 58(2022), 11 vom: 27. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rizzo, Alessandro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biliary tract cancer |
|---|
| Anmerkungen: |
Date Completed 14.11.2022 Date Revised 08.03.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/medicina58111543 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348770855 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348770855 | ||
| 003 | DE-627 | ||
| 005 | 20231226041034.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/medicina58111543 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348770855 | ||
| 035 | |a (NLM)36363500 | ||
| 035 | |a (PII)1543 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rizzo, Alessandro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer |b A Multicenter Real-World Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.11.2022 | ||
| 500 | |a Date Revised 08.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objectives: The ABC-06 and the NIFTY trials recently established the role of second-line chemotherapy (2L) in patients with advanced biliary tract cancer (BTC). Our real-world study aimed to explore 2L in BTC patients aged ≥ 70 years old and to compare their outcomes with younger subjects. Methods: Institutional registries across three academic medical centers were retrospectively reviewed. The Kaplan−Meier methods were used to estimate survival, and the log-rank test was used to make comparisons. Results: A total of 190 BTC patients treated with 2L were identified and included in the analysis. Among them, 52 (27.3%) were aged ≥ 70 years (range 70−87 years). No statistically significant differences in both median overall survival (mOS) and median progression-free survival (mPFS) were recorded between the elderly and younger patients. Absolute lymphocyte count < 1000/mmc (p < 0.001) and albumin level < 3 g/dL (p < 0.001) were independently associated with worse prognoses. Conclusions: The results of this real-world study suggest that for patients aged ≥ 70 years, 2L could be equally effective for younger patients with survival outcomes aligned to those from the ABC-06 and NIFTY trials. The delivery of 2L should be carefully evaluated and monitored in this patient subset | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biliary tract cancer | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a cholangiocarcinoma | |
| 650 | 4 | |a elderly | |
| 650 | 4 | |a second-line | |
| 700 | 1 | |a Salati, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Frega, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Merz, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Caputo, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Di Federico, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Palloni, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Carloni, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Ricci, Angela Dalia |e verfasserin |4 aut | |
| 700 | 1 | |a Gadaleta-Caldarola, Gennaro |e verfasserin |4 aut | |
| 700 | 1 | |a Messina, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Spallanzani, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Gelsomino, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Benatti, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Luppi, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Melisi, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Dominici, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Brandi, Giovanni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina (Kaunas, Lithuania) |d 1998 |g 58(2022), 11 vom: 27. Okt. |w (DE-627)NLM093687583 |x 1648-9144 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2022 |g number:11 |g day:27 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/medicina58111543 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2022 |e 11 |b 27 |c 10 | ||